To further demonstrate EGFR signaling–mediated CD73 expression in EGFR-mutated NSCLC, we treated mice bearing PC9 tumors and EGFRL858R/T790M genetically engineered mice (GEM) with osimertinib. This evidence concerns the gene NT5E and non-small cell lung carcinoma.